Allogeneic Stem Cell Transplantation (Allo-Sct) Severe Aplastic Anemia, a Single Center Experience in Bogotá, Colombia

Abstract

Allo-SCT from an HLA related or unrelated donor is the first line treatment for newly diagnosed patients with BMFS younger than 40 years, and for older patients that failed immunosuppressive therapy. Cohort retrospective analysis of BMFS patients receiving Allo-SCT in a mixed (pediatric-adult) transplant center in Bogota, Colombia, are reported. Log-rank tests(Lrt) analyses were used to determine the effects of age, conditioning regimen and year of treatment on survival. Between January 1993 and August 2011, 74 transplants were performed in 70 patients(52 acquired SAA,16 Fanconi Anemia and 2 pure red cell aplasia). Table 1 reflects patients and transplant characteristics. 70 grafts were obtained from HLA identical siblings, 3 from unrelated CBU and 1 from a haploidentical sibling. Conditioning regimens used were: RIC Cy-Flu-ATG(22), Cy-ATG(33) and Cy(12). 4 patients were conditioned with Campath containing regimens and 3 with other. Before 2004 most patients received Cs and MTX as GVHD prophylaxis, after 2004 Cs and MMF was used in the majority.